Results 161 to 170 of about 54,917 (299)

SGLT2 is upregulated to acquire cisplatin resistance and SGLT2 inhibition reduces cisplatin resistance in hepatoblastoma

Background: Cancer cells can alter glucose metabolism and regulate the expression of glucose transporters. Hepatoblastoma patients undergo cisplatin-based chemotherapy; however, 22.3% of patients develop cisplatin resistance and thus face a poor ...
Kondo, Takafumi, Honda, Shohei, Kobayashi, Nozomi, Fujiyoshi, Sunao, Taketomi, Akinobu, Ara, Momoko   +5 more
core   +1 more source

Early sodium‐glucose co‐transporter 2 inhibitor initiation is associated with improved cardiovascular outcomes in type 2 diabetes and acute coronary syndrome

Diabetic Medicine, EarlyView.
Abstract Aims Sodium‐glucose co‐transporter 2 inhibitors have demonstrated cardiovascular benefits in individuals with type 2 diabetes mellitus, but the optimal timing of initiation in those with acute coronary syndrome is not known. This study aims to assess if early therapy at discharge is superior to delayed or no therapy in reduction in major ...
Muhammad Usman Shah, Joanna Kate Ward, Alun Roebuck, Bala Srinivasan, Paul Edward Squires, Claire Elizabeth Hills, Maxime Inghels, Kelvin Lee   +7 more
wiley   +1 more source

Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in an adolescent with type 2 diabetes. [PDF]

JCEM Case Rep
Segev N, Brady RP, Dolan L, Shah AS.
europepmc   +1 more source

Heterogeneous Renal Response to Therapy in Type 2 Diabetes: Albuminuria Categories. [PDF]

J Clin Med
AlGhawi RJ, Albanki HA, Almahrous LM, Alabbasi FA, Zurkiyeh M, Alotaibi AB, Alkhunaizi AM.   +6 more
europepmc   +1 more source

SGLT2 Inhibitor [PDF]

, 2020
openaire   +1 more source

SGLT2-gátlókkal történő kezelés során kialakuló fertőzések kockázata és megelőzése

Az SGLT2 gátlók első vonalbeli kezelésként ajánlottak 2-es típusú cukorbetegség, krónikus vesebetegség és szívelégtelenség esetén, mivel igazoltan csökkentik a szív- és veseeredetű megbetegedéseket és a halálozást.
Kondráth, Mariann
core  

Sodium glucose cotransporter 2 inhibitors may mask malignancy-associated fluorodeoxyglucose uptake in the thyroid on positron emission tomography/computed tomography. [PDF]

Rev Assoc Med Bras (1992)
Alanli R, Kucukay MB, Koca AO, Ucmak G, Dogan M.   +4 more
europepmc   +1 more source

GLP‐1 Receptor Agonist Therapy Is Associated With Lower Risk of Lower Extremity Amputation in Adults With Type 2 Diabetes and Foot Ulcer Without Coded Peripheral Arterial Disease: A Hypothesis‐Generating Real‐World Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To compare lower extremity amputation (LEA) risk in adults with Type 2 diabetes and diabetic foot ulcer (DFU) treated with glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) versus other glucose‐lowering therapy, and to test whether coded peripheral arterial disease (PAD) modifies this association and replicates across comparator ...
Hani Robinson, Mustafa Yassin, Dror Robinson, Mohamad Eisa, Waseem Abu Rashed, Feras Qawasmi, Assil Mahamid, Hamza Murad, Muhammad Khatib   +8 more
wiley   +1 more source

SGLT2-inhibitors in treatment of the heart failure

Sydämen vajaatoiminnassa sydän ei pysty pumppaamaan tarpeeksi verta elimistön tarpeisiin nähden. Kyseessä ei ole itsenäinen sairaus vaan oireyhtymä, jonka taustalla on useita sydänsairauksia.
Kanerva, Noora, Härmä, Miisa
core   +1 more source

Sodium-Glucose Cotransporter 2-Mediated Glucose Uptake Contributes to Glycogen Accumulation in Clear Cell Renal Cell Carcinoma: Implications for Clear Cell Morphology and Potential Therapeutic Relevance. [PDF]

Int J Mol Sci
Nagata Y, Tomisaki I, Matsukawa T, Quynh NT, Tsubonuma Y, Sugita Y, Nawata A, Kokubu K, Baba R, Morimoto H, Ogawa K, Wada K, Fujimoto N.   +12 more
europepmc   +1 more source